Pfizer: Pfizer’s experimental COFID-19 vaccine appears to be working. The vaccine has been shown to be over 90 percent effective, according to clinical results released by the company on Monday.
This news is the result of an interim analysis of a study on 43,538 volunteers, 42% of which “from different backgrounds”.
Each participant received two injections at 21-day intervals. The analysis compared the number of COVID-19 cases among volunteers who received the vaccine with a group of volunteers of the same size who were injected with a fluid that did not contain the vaccine.
In a press release from Pfizer and its partner BioNTech, the company said results from 94 valuable cases of COVID-19 among study participants showed the vaccine was more than 90 percent effective in preventing COVID-19. The Food and Drug Administration has set a minimum efficiency of 50%.
It is the first ongoing COVID-19 vaccine that shows data has exceeded this limit.
“I’m pretty optimistic. I’ve been developing vaccines for over 35 years,” he said. William Gruber, Senior Vice President of Clinical Vaccine Research and Development at Pfizer. “But it’s excellent and I think it speaks not only of the potential of this vaccine but also of the possibility of other vaccines being developed for COVID-19.”
Read More: PS5: Has Package Contents Leaked Online? You should know that
“This result is approaching the highest of expectations,” said an email comment from Shane Crotty, a professor at the La Jolla Institute of Immunology, Institute of Immunology, Center for Disease Research. infectious diseases and at the Vaccine Research Center. “Over 90% effectiveness in disease prevention with 94 COVID-19 cases to evaluate is an excellent result! It would be great to see more data, but these are very compelling numbers.”
While this review looks promising. It does not provide enough information on the Pfizer vaccine to require FDA approval for distribution.
The service informed producers that the data of at least half of the volunteers will be monitored for at least two months. The FDA says the reason for this requirement is that the most dangerous side effects of a vaccine occur within two months of the last injection. According to Pfizer, the data will not be available until the third week of November.
Pfizer and BioNTech
The company did not specify the severity of the COVID-19 cases that occurred in the study or whether any of them required hospitalization.
Natalie Dean, biostatistics at the University of Florida, says she is cautiously optimistic but is awaiting more data.
“Many questions remain unanswered, such as the vaccine’s effectiveness in different age groups. And the extent to which it prevents infections and serious illness,” Dean wrote in an email to NPR. “But for the given primary symptom of laboratory-confirmed disease in the entire population tested, the numbers look very good.”
The Pfizer vaccine study is called an event study. It doesn’t last for a specific period of time. Instead, the study will continue. And will not be considered complete until 164 cases of COVID-19 have been reported in all volunteers.
According to its published magazine. The company planned to conduct four interim trials that would lead to a prohibited number of COVID-19 cases. The results, released on Monday. Come from the second time the company has agreed with the FDA not to conduct the first test.